Media ReleasesINOVIQ

View All INOVIQ News


INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out


-- INOVIQ engages US-based Percorso Life Sciences to provide contract sales force and logistics services to accelerate commercial roll-out of EXO-NET® products in the USA
-- Contract sales force covers the key East-Coast, West-Coast and Mid-West US regions
-- Services include marketing, sales, inventory, logistics and warehousing of EXO-NET research tools to academia and biopharma customers
-- Engagement in line with INOVIQ’s strategy to first commercialise EXO-NET as a research tool in the global exosome research market, which is expected to reach US$661 million by 2026, with US representing 41.5% of market 

Melbourne, Australia, 21 July 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is pleased to announce that it has engaged US-based Percorso Life Sciences LLC (Percorso) under a Services Agreement to provide contract sales and logistics services, accelerating the commercial roll-out of INOVIQ’s EXO-NET research products in the USA.

CEO Dr Leearne Hinch said: “This agreement with Percorso Life Sciences is a key step toward driving our EXO-NET research tool sales in the largest geographic market segment for exosome research products globally. It signals a ramp up in our commercial focus for EXO-NET and is another important milestone for INOVIQ. It also expands access to potential collaboration opportunities for exosome-based diagnostic and therapeutic applications. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.